中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
6期
40-41
,共2页
慢性阻塞性肺疾病%辛伐他汀
慢性阻塞性肺疾病%辛伐他汀
만성조새성폐질병%신벌타정
Chronic obstructive pulmonary disease%Simvastatin
目的：观察小剂量辛伐他汀（10 mg/次，每晚1次）为期1年的治疗对中度稳定期慢性阻塞性肺疾病（COPD）患者生活质量的影响。方法：选取符合纳入标准的60例中度稳定期慢性阻塞性肺疾病患者，按照随机数字表法将其分为试验组和对照组各30例，对照组采取常规治疗1年，试验组在常规治疗的基础上加用辛伐他汀10 mg/次，每晚1次，口服1年，记录并比较1年前后两组患者COPD评估测试（CAT）评分。结果：两组患者治疗前CAT评分比较差异无统计学意义（P>0.05），治疗1年后两组CAT评分均明显优于治疗前，且试验组CAT评分明显优于对照组，比较差异均有统计学意义（P<0.05）。结论：小剂量辛伐他汀可以改善COPD患者生活质量，值得在临床上推广。
目的：觀察小劑量辛伐他汀（10 mg/次，每晚1次）為期1年的治療對中度穩定期慢性阻塞性肺疾病（COPD）患者生活質量的影響。方法：選取符閤納入標準的60例中度穩定期慢性阻塞性肺疾病患者，按照隨機數字錶法將其分為試驗組和對照組各30例，對照組採取常規治療1年，試驗組在常規治療的基礎上加用辛伐他汀10 mg/次，每晚1次，口服1年，記錄併比較1年前後兩組患者COPD評估測試（CAT）評分。結果：兩組患者治療前CAT評分比較差異無統計學意義（P>0.05），治療1年後兩組CAT評分均明顯優于治療前，且試驗組CAT評分明顯優于對照組，比較差異均有統計學意義（P<0.05）。結論：小劑量辛伐他汀可以改善COPD患者生活質量，值得在臨床上推廣。
목적：관찰소제량신벌타정（10 mg/차，매만1차）위기1년적치료대중도은정기만성조새성폐질병（COPD）환자생활질량적영향。방법：선취부합납입표준적60례중도은정기만성조새성폐질병환자，안조수궤수자표법장기분위시험조화대조조각30례，대조조채취상규치료1년，시험조재상규치료적기출상가용신벌타정10 mg/차，매만1차，구복1년，기록병비교1년전후량조환자COPD평고측시（CAT）평분。결과：량조환자치료전CAT평분비교차이무통계학의의（P>0.05），치료1년후량조CAT평분균명현우우치료전，차시험조CAT평분명현우우대조조，비교차이균유통계학의의（P<0.05）。결론：소제량신벌타정가이개선COPD환자생활질량，치득재림상상추엄。
Objective:To observe the low-dose simvastatin(10 mg/times,once a night)a period of one year of treatment for moderate stable chronic obstructive pulmonary disease(COPD)patients quality of life impact.Method:60 patients with moderate stable chronic obstructive pulmonary disease were randomly divided into the experimental group and the control group,30 cases in each group.The control group was treated with conventional therapy for one year,the experimental group was treated with oral simvastatin 10 mg/times,once a night for 1 year on the basis of conventional therapy. COPD assessment test(CAT)score of the two groups before and after one year were recorded and compared.Result:Before treatment,the CAT scores had no significant differences between the two groups(P>0.05),after one year of treatment,CAT scores of the two groups were significantly better than before treatment,and CAT of the experimental group was significantly better than the control group,the differences were statistically significant(P<0.05). Conclusion:Low-dose simvastatin can improve the quality of life in patients with COPD,it is worth promoting in clinical practice.
